22.728 articles found

Rapidly Progressing Mitral Regurgitation After Cabergolin Treatment

Uz, Ömer, Kardeşoğlu, Ejder, Aparcı, Mustafa, Özmen, Namık, Cebeci, Bekir Sıtkı

Balkan Medical Journal, Vol. 2008 No. 3 · 2014-08-06

Brain-specific delivery of dopamine mediated by n,n-dimethyl amino group for the treatment of Parkinson's disease.

Li Y, Zhou Y, Qi B, Gong T, Sun X, Fu Y, Zhang Z.

Mol Pharm · 2014-08-06

DOI: 10.1021/mp500352pPMID: 25072272

Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates.

Morin N, Di Paolo T.

Front Neurol · 2014-08-05

DOI: 10.3389/fneur.2014.00144PMID: 25140165

Can phototherapy ameliorate the progression of Parkinson's disease?

Jang I, Han C.

Photomed Laser Surg · 2014-08-05

DOI: 10.1089/pho.2014.3765PMID: 25093424

[The use of neuromodulation for the treatment of tremor].

Bendersky D, Ajler P, Yampolsky C.

Surg Neurol Int · 2014-08-04

DOI: 10.4103/2152-7806.137944PMID: 25165613

Treatment of early Parkinson's disease.

Pahwa R, Lyons KE.

Curr Opin Neurol · 2014-08-01

DOI: 10.1097/wco.0000000000000113PMID: 24950010

Treatment of advanced Parkinson's disease.

Giugni JC, Okun MS.

Curr Opin Neurol · 2014-08-01

DOI: 10.1097/wco.0000000000000118PMID: 24978634

New treatment options for the management of restless leg syndrome.

Toro BE.

J Neurosci Nurs · 2014-08-01

DOI: 10.1097/jnn.0000000000000068PMID: 24992148

Moderate evidence exists for occupational therapy-related interventions for people with Parkinson's disease in physical activity training, environmental cues and individualised programmes promoting personal control and quality of life.

Liddle J, Eagles R.

Aust Occup Ther J · 2014-08-01

DOI: 10.1111/1440-1630.12153PMID: 25154449

[Neurological common diseases in the super-elder society. Topics: IV. Parkinson's disease; 2. Current and new drugs for initial treatment of Parkinson's disease].

Hasegawa T.

Nihon Naika Gakkai Zasshi · 2014-08-01

DOI: 10.2169/naika.103.1861PMID: 25654881

Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease.

Zhao JW, Dyson SC, Kriegel C, Tyers P, He X, Fahmy TM, Metcalfe SM, Barker RA.

Dis Model Mech · 2014-08-01

DOI: 10.1242/dmm.015859PMID: 25085990

Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders.

Irwin RW, Solinsky CM, Brinton RD.

Front Cell Neurosci · 2014-07-30

DOI: 10.3389/fncel.2014.00203PMID: 25126056